Advice
following an abbreviated submission:
deuruxolitinib (Leqselvi®) is accepted for use within NHSScotland.
Indication under review: treatment of adult patients with severe alopecia areata.
Deuruxolitinib offers an additional treatment choice in the therapeutic class of Janus kinase (JAK) inhibitors.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice407KB (PDF)
Medicine details
- Medicine name:
- deuruxolitinib (Leqselvi)
- SMC ID:
- SMC2968
- Indication:
Treatment of adult patients with severe alopecia areata.
- Pharmaceutical company
- Sun Pharmaceuticals UK Ltd
- BNF chapter
- Skin
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 October 2026